Case Report: FIA plus venetoclax in a patient on hemodialysis.
The safe and effective delivery of curative cytotoxic chemotherapy for acute myeloid leukemia (AML) in patients receiving intermittent hemodialysis (IHD) for end-stage renal disease (ESRD) remains a c
APA
Herstein JE, Marx KR, et al. (2025). Case Report: FIA plus venetoclax in a patient on hemodialysis.. Frontiers in oncology, 15, 1740357. https://doi.org/10.3389/fonc.2025.1740357
MLA
Herstein JE, et al.. "Case Report: FIA plus venetoclax in a patient on hemodialysis.." Frontiers in oncology, vol. 15, 2025, pp. 1740357.
PMID
41626172
Abstract
The safe and effective delivery of curative cytotoxic chemotherapy for acute myeloid leukemia (AML) in patients receiving intermittent hemodialysis (IHD) for end-stage renal disease (ESRD) remains a clinical challenge; pharmacological and logistical barriers necessitate close interdisciplinary coordination. In this case, we report a 65-year-old female patient with chronic ESRD on IHD and newly diagnosed AML who achieved complete remission (CR) after treatment with fludarabine, idarubicin, and cytarabine plus venetoclax (i.e., FIA + venetoclax).